Aldeyra Therapeutics, Inc.
ALDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.11 | 0.14 | 7.01 | 1.04 |
| FCF Yield | -14.56% | -14.66% | -13.94% | -19.69% |
| EV / EBITDA | -4.80 | -2.26 | -4.63 | -0.04 |
| Quality | ||||
| ROIC | -69.65% | -30.25% | -37.51% | -25.37% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.77 | 0.81 | 0.91 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -42.48% | 46.47% | -33.10% | -13.52% |
| Safety | ||||
| Net Debt / EBITDA | 0.73 | 3.61 | 2.14 | 3.84 |
| Interest Coverage | -31.21 | -20.66 | -37.00 | -32.27 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -263.86 | -1,858.55 | -188.53 | -1,408.85 |